Abstract：Objective: To evaluate the efficacy and security ofatorvastatin combination with ezetimibe in patients with acute coronary syndrome(ACS). Methods: A total of 79 patients with ACS were randomized to receive atorvastatin (20 mg/d) and ezetimibe (10 mg/d, combination group, n=41) or atorvastatin (20 mg/d) alone (atorvastatin group, n=38). Levels of lipids of two groups were detected as well as ALT and CK after two weeks therapy. The cardiovascular events and related sideeffects were observed during two weeks of the treatment. Results: Compared to baseline, the levels of total cholesterol, triglyceride and low density lipoproteincholesterol were reduced after two weeks in two groups. The levels of cholesterol in combination group were significantly reduced than those in atorvastatin group (P<0.05).The incidence of cardiovascular events (recurrence of angina pectoris and acute myocardial infarction) in combination group was lower than that in atorvastatin group (P<0.05). Conclusion: The combined atorvastatin and ezetimibe therapy early after ACS had good security, and was superior to atorvastatin alone on reducing the levels of cholesterol and the incidence of cardiovascular events.
王强, 孙建辉. 早期阿托伐他汀联合依折麦布治疗急性冠脉综合征临床观察[J]. 江苏大学学报:医学版, 2012, 22(5): 426-429.
WANG Qiang, Sun-Jian-Hui. Effect of atorvastatin, alone and in combination with ezetimibe in the treatment of patients with acute coronary syndrome. Journal of Jiangsu University(Medicine Edition), 2012, 22(5): 426-429.
2012, Vol. 22 
